Adios #ISPORBarcelona, you've been great! We are saving the date for #ISPORCopenhagen in #2019! @ISPORorg #RealWorldEvidence #research #HEOR #MA #digitalhealth #BYOD
The last session of the day at #ISPORBarcelona by the @ISPORorg Statistical Methods in #HEOR Sig on Indirect Treatment Comparisons #ITC https://t.co/hq6fEDCdTi
Are you finding that payer advisory board proving difficult to organise? Visit us at #ISPORbarcelona, stand 518, to get a live demonstration our virtual advisory board solution, TRAVELLESS https://t.co/Ypjgejeo2j https://t.co/g0tyKFhGW8
Should we propose budget caps? If the question was so simple, I would say no, don't do it. It is too risky. If you put budget caps in place, there will be overspending and cost-sharing. We need financial stability - Geert van Maanen #ISPORBarcelona
Tegoroczna odsłona #ISPORBarcelona przyciągnęła rekordową liczbę 5,5 tysiąca uczestników z całego świata. @MinZdrowia @ISPORorg https://t.co/MZBEiv9mgW
#Diabetes studies, database studies, confounding by indication, the use of R, electronic patient-reported outcomes (#ePROs), and the #value of #diagnostic information to be presented in 30 minutes at #ISPORBarcelona
Thanks to our top influencers for Wednesday, 14 November at ISPOR Europe 2018. #ISPORBarcelona #HEOR https://t.co/5dvCHbTZfh
Now at the last session at #ISPORBarcelona #ispor2018 Really enjoyed my first ISPOR Congress! @IDIAPJGol @sidiapdatabase @anchoitaAGL https://t.co/9h25QPtzxA
Congratulations @gorrycm on your great research and for residing in the top 10% of @ISPORorg submissions this year! 🎉 #ISPORBarcelona
@ISPORorg Policy Measures to Maximise Patient Access after Introduction of Biosimilars. We see that Biosimilars can provide more health/save more money for a healthcare system. Lack of Incentives from Policy makers to increase use #ISPORbarcelona https://t.co/cZ5g9OKj5W
Delighted to present my poster on the 'Construct validity of EQ-5D in....' please drop by at 12.15 to find out!! #ISPORBarcelona @INFO_NCPE https://t.co/qD2hj4HS99
Félix Lobo @uc3m give a pragmatic answer to expenditure caps: “If our wold was perfect (robust pharmaceutical policy) we would not need expenditure caps but because it isn’t they are a second best option. However they must be improved”. ISPOR 3rd Plenary session #ISPORBarcelona.
Claire Gorry presenting her poster on construct validity of EQ-5D in non-melanoma skin cancer @gorrycm #ISPORBarcelona #ISPORstudents https://t.co/tYkxB0YnFl
Final Day at #ISPORBarcelona with @OAConsulting and Harvey Walsh at the @OPENHealth stand 715. The last of our 10 posters is also being presented today for the Patient Reported Outcomes Team.
Final #ISPORBarcelona workshop had some great audience participation from across the industry and gave us some great ideas on how to increase patient access to #biosimilars in the off-patent biological market. https://t.co/r2W8QVbJSv